182 related articles for article (PubMed ID: 29478040)
1. Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies.
Calise SJ; Zheng B; Hasegawa T; Satoh M; Isailovic N; Ceribelli A; Andrade LEC; Boylan K; Cavazzana I; Fritzler MJ; de la Torre IG; Hiepe F; Kohl K; Selmi C; Shoenfeld Y; Tincani A; Chan EKL;
Clin Chem Lab Med; 2018 Sep; 56(10):1789-1798. PubMed ID: 29478040
[TBL] [Abstract][Full Text] [Related]
2. Association of Autoantibody to Rods and Rings with Hepatitis C Outcome and Viral Load.
Dhaouadi T; Abdellatif J; Jallouli M; Mejdoubi M; Sfar I; Mouelhi L; Aouini S; Ben Abdallah T; Gorgi Y
Viral Immunol; 2019 Jun; 32(5):214-220. PubMed ID: 31081724
[TBL] [Abstract][Full Text] [Related]
3. Anti-rods/rings autoantibody generation in hepatitis C patients during interferon-α/ribavirin therapy.
Keppeke GD; Calise SJ; Chan EK; Andrade LE
World J Gastroenterol; 2016 Feb; 22(6):1966-74. PubMed ID: 26877604
[TBL] [Abstract][Full Text] [Related]
4. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
[TBL] [Abstract][Full Text] [Related]
5. Temporal evolution of human autoantibody response to cytoplasmic rods and rings structure during anti-HCV therapy with ribavirin and interferon-α.
Keppeke GD; Satoh M; Ferraz ML; Chan EK; Andrade LE
Immunol Res; 2014 Oct; 60(1):38-49. PubMed ID: 24845459
[TBL] [Abstract][Full Text] [Related]
6. High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Berardi S; Lodato F; Gramenzi A; D'Errico A; Lenzi M; Bontadini A; Morelli MC; Tamè MR; Piscaglia F; Biselli M; Sama C; Mazzella G; Pinna AD; Grazi G; Bernardi M; Andreone P
Gut; 2007 Feb; 56(2):237-42. PubMed ID: 16798778
[TBL] [Abstract][Full Text] [Related]
7. [Ischemic anterior optic neuropathy complicating interferon alpha-2a and ribavirin treatment for acute hepatitis C].
Yaghi C; Baz P; Koussa S; Daniel F; Haddad F; Sayegh R
Gastroenterol Clin Biol; 2005 May; 29(5):616-7. PubMed ID: 15980766
[No Abstract] [Full Text] [Related]
8. Development of a recombinant cell-based indirect immunofluorescence assay (RC-IFA) for the determination of autoantibodies against "rings and rods"-associated inosine-5'-monophosphate dehydrogenase 2 in viral hepatitis C.
Probst C; Radzimski C; Blöcker IM; Teegen B; Bogdanos DP; Stöcker W; Komorowski L
Clin Chim Acta; 2013 Mar; 418():91-6. PubMed ID: 23333419
[TBL] [Abstract][Full Text] [Related]
9. Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir.
Marquez-Azalgara V; Hussaini T; Erb SR; Yoshida EM
Ann Hepatol; 2014; 13(5):565-7. PubMed ID: 25152991
[TBL] [Abstract][Full Text] [Related]
10. Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.
Fuhrmann V; Kramer L; Bauer E; Laferl H; Tucek G; Dekan G; Schenk P
Dig Dis Sci; 2004; 49(11-12):1966-70. PubMed ID: 15628735
[No Abstract] [Full Text] [Related]
11. Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C.
Covini G; Carcamo WC; Bredi E; von Mühlen CA; Colombo M; Chan EK
Antivir Ther; 2012; 17(5):805-11. PubMed ID: 22293655
[TBL] [Abstract][Full Text] [Related]
12. [Severe ocular bacterial infection associated with pegylated interferon and ribavirin treatment for hepatitis C].
Khalil A; Gonzalez F; El Riachy E; Lucidarme D; Filoche B
Gastroenterol Clin Biol; 2005 Nov; 29(11):1187-8. PubMed ID: 16505773
[No Abstract] [Full Text] [Related]
13. Side effects. Bone problems may occur with hepatitis treatment.
TreatmentUpdate; 2000 Sep; 12(6):7-8. PubMed ID: 12132465
[No Abstract] [Full Text] [Related]
14. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
Quinn D; Kuchler E; Deming P; Arora S
Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
[No Abstract] [Full Text] [Related]
15. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
[No Abstract] [Full Text] [Related]
16. Multiplex autoantibody detection for autoimmune liver diseases and autoimmune gastritis.
Vanderlocht J; van der Cruys M; Stals F; Bakker-Jonges L; Damoiseaux J
J Immunol Methods; 2017 Sep; 448():21-25. PubMed ID: 28522403
[TBL] [Abstract][Full Text] [Related]
17. [Use of anxiolytics and antidepressants before and after treatment with interferon-alpha and ribavirin in patients with hepatitis C].
García-Toro M; Vilella Martorell A; Carral Martínez M; Jimeno Beltrán T; Román Ruiz del Moral Y; Pradas Guerrero C; Gili Planas M; Roca Bennasar M
Gastroenterol Hepatol; 2011 Apr; 34(4):307-8. PubMed ID: 21376422
[No Abstract] [Full Text] [Related]
18. Diagnostic laboratory tests for systemic autoimmune rheumatic diseases: unmet needs towards harmonization.
Meroni PL; Borghi MO
Clin Chem Lab Med; 2018 Sep; 56(10):1743-1748. PubMed ID: 29708880
[No Abstract] [Full Text] [Related]
19. Reversible decompensated liver disease as a possible complication of pegylated-interferon alfa 2b and ribavirin for recurrent hepatitis C.
Mukherjee S
J Gastroenterol Hepatol; 2004 Jun; 19(6):723-4. PubMed ID: 15151639
[No Abstract] [Full Text] [Related]
20. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.
Bani-Sadr F; Carrat F; Pol S; Hor R; Rosenthal E; Goujard C; Morand P; Lunel-Fabiani F; Salmon-Ceron D; Piroth L; Pialoux G; Bentata M; Cacoub P; Perronne C;
J Acquir Immune Defic Syndr; 2005 Sep; 40(1):47-52. PubMed ID: 16123681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
